ЛИТЕРАТУРА

1. Данилова Л.И. Болезни щитовидной железы и ассоциированные с ними заболевания / Л.И. Данилова // «Heiwadow ofset» Минск - Нагасаки, 2005, - 470 с.

2. Данилова Л.И. Влияние монотерапии пентоксифиллином на

имуноцитокиновый статус больных аутоиммунным тироидитом и офтальмопатией // Медицинские новости.

3. Мельник И.Р., Данилова Л.И., Космачева С.М. и др. Влияние терапии пентоксифиллином и глюкортикостероидами на апоптоз и пролиферативную активность мононуклеаров периферической крови у больных с сочетанием болезни Грейвса-Базедова и аутоиммунной офтальмопатии // Медицинские новости. - 2011. - № 4. - С. 97 - 100.

4. Balazs C., Kiss E., Vamos A. et al. Beneficial effect of pentoxifylline on thyroid associated ophthalmopathy (TAO): a pilot study // J. Clin. Endocrinol. Metab. - 1997. - Vol. 82, № 6. - P. 1999-2002.

5. Bartalena L. Glucocorticoids for Graves’ Ophthalmopathy: how and when // J Clin Endocrinol Metab. - 2005. - Vol. 90. - P. 5497 - 5499.

6. Bartalena L., Marcocci C., Tanda M.L. et al. An update on medical management of Graves’ ophthalmopathy // J Endocrinol Invest. - 2005. - Vol. 28. - P. 469 - 478.

7. Bartalena L., Marcocci C., Tanda M.L. Management of thyroid eye disease // Eur J Nucl Med. - 2002. - Vol. 29. - P. 458-465.

8. Bartalena L., Pinchera A., Marcocci C. Graives' ophthalmopathy: a preventable diesease? // European Journal of Endocrinology. - 2002. - Vol. 146. - P. 457-461.

9. Bartalena L., Pinchera A., Marcocci C. Management of Graves' ophthalmopathy: reality and perspectives // Endocrine Reviws. - 2000. - Vol. 21. - P. 168 - 199.

10. Bartalena L., Tanda M.L, Piantanida E., Lai A. Glucocorticoids and outcome of radioactive iodine therapy for Graves’ hyperthyroidism // European Journal of Endocrinology. - 2005. - Vol. 153. - P. 13 - 14.

11. Cawood T., Moriarty P., O'Shea D.

12. Cawood T.J, Moriarty P., O’Farrelly C., O'Shea D. Smoking and thyroid- associated ophthalmopathy: a novel explanation of the biological link // J Clin Endocrinol Metab. - 2007. - Vol. 92, № 1. - P. 59 - 64.

13. Chang T.C., Liao S.L. Slow-release lanreotide in GO: a double-randomized, placebo-controlled clinical trial // J Endocrinol Invest. - 2006. - Vol. 29, № 5. - P. 413 - 422.

14. Cockerham K.P., Chan S. S. Thyroid Eye Disease // Neurol Clin. - 2010. - Vol. 28. - P. 729 - 755.

15. Dickinson J., Perros P. Thyroid-associated orbitopathy: who and how to treat // Endocrinol Metab Clin North Am. - 2009. - Vol. 38. - P. 373 - 388.

16. Eckstein A., Quadbeck B., Mueller G. et al. Impact of smoking on the response to treatment of thyroid associated ophthalmopathy // Br. J. Ophthalmol. - 2003. - Vol. 87. - P. 773 - 776.

17. Eckstein A.K., Plicht M., Lax H. et al. Thyrotropin receptor autoantibodies are independent risk factors for Graves’ ophthalmopathy and help to predict severity and outcome of the disease // J Clin Endocrinol Metab. - 2006. - Vol. 91, № 9. - P.3464 - 3470.

18. European Group of Graves’ Orbitopathy (EUGOGO), Perros P., Baldeschi L., Boboridis K. et al. A questionnaire survey on the management of Graves’ orbitopathy in Europe // European Journal of Endocrinology. - 2006. - Vol. 155, № 2. - P. 207 - 211.

19. Fassi D.El., Nielsen C.H., Bonnema S.J. et al. B lymphocyte depletion with the monoclonal antibody rituximab in Graves’ disease: a controlled pilot study // J Clin Endocrinol Metab. - 2007. - Vol. 92, № 5. - P. 1769 - 1772.

20. Goh M.S.Y., McNab A.A. Orbital decompression in Graves’ orbitopathy: efficacy and safety // Internal Medicine Journal. - 2005. - Vol. 35. - P. 586 - 591.

21. Kahaly G.J., Petrak F., Hardt J. Psychosocial morbidity of Graves’ orbitopathy // Clinical Endocrinology. - 2005. - Vol. 63. - P. 395 - 402.

22.

23. Kahaly G.J., Sler HP., Pitz S., Hommel G. Low-versus high-dose radiotherapy for Graves’ ophthalmopathy: a randomized, single blind trial // J Clin Endocrinol Metab. - 2000. - Vol. 85, № 1. - P. 102 - 108.

24. Krassas G. E., Gogakos A. Thyroid-associated opthalmopathy in juvenile Graves’ disease. Clinical, endocrine and therapeutic aspects // J Pediatr Endocrinol Metab.

- 2006. - Vol. 19. - P. 1193 - 1206.

25. Krassas G.E. Treatment of juvenile Graves’ disease and its ophthalmic complication: the ‘European way’ // European Journal of Endocrinology. - 2004.

- Vol. 150. - P. 407 - 414.

26. Krassas G.E., Boboridis K. Recent developments in the medical treatment of thyroid eye disease // Orbit. - 2006. - Vol. 25. - P. 117 - 122.

27. Lai A., Sassi L., Compri E. et al. Lower dose prednisone prevents radioiodine- associated exacerbation of initially mild or absent Graves’ orbitopathy: a retrospective cohort study // J Clin Endocrinol Metab. - 2010. - Vol. 95, № 3. - P. 1333 - 1337.

28. Marcocci C., Bartalena L., Rocchi R. et al. Long-Term safety of orbital radiotherapy for Graves’ ophthalmopathy // J Clin Endocrinol Metab. - 2003. - Vol. 88, № 8. - P. 3561 - 3566.

29. Marcocci C., Pinchera A., Marino M. A treatment strategy for Graves’ ophthalmopathy // Nat Clin Pract Endocrinol Metab. - 2007. - Vol. 3. - P. 430 - 436.

30. Owecki M., Sowinski J. Acute myocardial infarction during high-dose methylprednisolone therapy for Graves’ ophthalmopathy // Pharm World Sci. - 2006. - Vol. 28. - P. 73 - 75.

31. Paridaens et al. The effect of etanercept on Graves’ ophthalmopathy: a pilot study // Eye. - 2005. - Vol. 19. - P. 1286 - 1289.

32. Perros P., Kendall-Taylor P., Neoh C. et al. A prospective study of the effects of radioiodine therapy for hyperthyroidism in patients with minimally active Graves’ ophthalmopathy // J Clin Endocrinol Metab.

33. Salvi M., Vannucchi G., Campi I. et al. Treatment of Graves’ disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study // European journal of endocrinology. - 2007. - Vol. 156. - P. 33 - 40.

34. Sisson J.C., Schipper M.J., Nelson C.C. et al. Radioiodine Therapy and Graves' Ophthalmopathy // Journal of Nuclear Medicine. - 2008. - Vol. 49, № 6. - P. 923

- 930.

35. Stan M.N., Garrity J.A., Bradley E.A. et al. Randomized, double-blind, placebo- controlled trial of long-acting octreotide for treatment of Graves’ ophthalmopathy // J Clin Endocrinol Metab. - 2006. - Vol. 91, № 12. - P. 4817 - 4824.

36. Stiebel-Kalish H., Robenshtok E., Hasanreisoglu M. et al. Treatment modalities for Graves’ ophthalmopathy: systematic review and metaanalysis // J Endocrinol Invest. - 2009. - Vol. 94, № 8. - P. 2708 - 2716.

37. Vannucchi G., Campi I., Covelli D. et al. Graves’ orbitopathy activation after radioactive iodine therapy with and without steroid prophylaxis // J Clin Endocrinol Metab. - 2009. - Vol. 94, № 9. - P. 3381 - 3386.

38. Wemeau J.L., Caron P., Beckers A. et al. Octreotide (long-acting release formulation) treatment in patients with Graves’ orbitopathy: clinical results of a four-month, randomized, placebo-controlled, double-blind study // J Clin Endocrinol Metab. - 2005. - Vol. 90, № 2. - P. 841 - 848.

39. Wiersinga W.M. Retrobulbar irradiation in Graves’ orbitopathy: the Dutch experience // Ophthalmic plastic and reconstructive surgery. - 2002. Vol. 18, № 3.

- P. 175 - 176.

Приложение 1